The global glycomics market is poised to reach USD 1,211.4 Million by
2021 from USD 649.5 Million in 2016, at a CAGR of 13.3%. Factors such as
increasing government and private funding for glycomics and proteomics
research and growing R&D expenditure by pharmaceutical and biotechnology
companies are the key drivers for the growth of the market. Whereas, the
high degree of consolidation is expected to restrict the entry of new
players in the market, and thereby hinder its growth.

On the basis of product, the market is segmented into enzymes,
instruments, kits, and reagents. The enzymes segment is projected to
grow at the highest CAGR during the forecast period. This growth is
mainly attributed to their consumable nature and wide applications in a
variety of R&D and drug discovery procedures. The enzymes segment is
further divided into glycosidases, glycosyltransferases, neuraminidases,
sialyltransferases, and other enzymes.

On the basis of application, the market is segmented into diagnostics,
drug discovery & development, oncology, immunology, and other
applications. In 2016, the drug discovery and development segment is
expected to account for the largest share of the market. This growth can
be attributed to increase in R&D activities for the development of novel
drugs and therapies.

On the basis of end user, the glycomics market is segmented into
academic research institutes, pharmaceutical & biotechnology companies,
and CROs. In 2016, the academic research institutes segment is projected
to account for the largest share of the market. This growth can be
attributed to the increasing government and private funding for
proteomic and glycomics research.